ORMP
Oramed Pharmaceuticals Inc.
$4.06
+0.06 (+1.50%)
At close · Jul 15
Market Cap
$165.75M
Shares
40,926,081
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.06
Open$4.01
Day$3.91–4.06
52W$1.85–5.19
Avg vol 30d413K
Short int878K · 2.1% float · 1.2d
Short vol46%
DataJan 2020–Jul 2026
Filing10-Q · May 19
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 19, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
−2%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
66%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+18%
trailing
YTD return
+53%
this year
Relative strength
+8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
2 of 64 funds reported for Jun 30 · net +12.2K sh shares · +1 new
Insider flow
Distributing
Net -$942.2K over 90 days · 100% sells
Short interest
Rising
2.14% of float · ▲ +53.9% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
+49%
Y/Y
Gross margin
1%
EPS growth
+413%
Y/Y
Free cash flow
$-9.2M
Valuation
P/E 1.6
below peers
Buyback
$469.0K
authorized
Balance sheet
$45.9M
net cash
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
66%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
2 of 64 funds reported for Jun 30 · net +12.2K sh shares · +1 new
Insider flow
Distributing
Net -$942.2K over 90 days · 100% sells
Short interest
Rising
2.14% of float · ▲ +53.9% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $4 · 66%
52-wk high $5
vs 200-day avg +21%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORMP
this stock
Oramed Pharmaceuticals Inc.
|
$165.75M | +52.8% | — | 1.6 | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +2.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORMP | -5.4% | +5.7% | +18.0% | -15.6% | +52.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -6.6% | +5.9% | +7.9% | -16.7% | +42.1% |
Capital returns
Latest dividend
$0.25
/ share · ex Jan 16, 2026
Paid (TTM)
$0.25
/ share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program
· as of Mar 31, 2026
Authorized
$469,000
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.